Analysts Anticipate Selecta Biosciences, Inc. (NASDAQ:SELB) Will Announce Quarterly Sales of $20.58 Million

Brokerages expect Selecta Biosciences, Inc. (NASDAQ:SELB) to post $20.58 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Selecta Biosciences’ earnings. The highest sales estimate is $21.15 million and the lowest is $20.00 million. Selecta Biosciences reported sales of $11.95 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 72.2%. The business is scheduled to issue its next quarterly earnings report on Thursday, March 10th.

According to Zacks, analysts expect that Selecta Biosciences will report full-year sales of $63.11 million for the current financial year, with estimates ranging from $51.08 million to $75.14 million. For the next fiscal year, analysts expect that the business will post sales of $73.98 million, with estimates ranging from $55.00 million to $92.96 million. Zacks’ sales calculations are an average based on a survey of research analysts that cover Selecta Biosciences.

Selecta Biosciences (NASDAQ:SELB) last issued its earnings results on Monday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.09). During the same quarter in the previous year, the business posted ($0.09) EPS.

SELB has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, November 13th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Selecta Biosciences in a report on Monday, November 15th. Finally, Needham & Company LLC lifted their price target on shares of Selecta Biosciences from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, November 1st. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $7.46.

In related news, CEO Carsten Brunn sold 15,313 shares of the business’s stock in a transaction on Wednesday, October 13th. The shares were sold at an average price of $4.39, for a total value of $67,224.07. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 24.00% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in Selecta Biosciences in the second quarter valued at $133,000. Marshall Wace LLP bought a new stake in Selecta Biosciences in the second quarter valued at $1,272,000. Geode Capital Management LLC increased its stake in Selecta Biosciences by 16.0% in the second quarter. Geode Capital Management LLC now owns 1,622,248 shares of the company’s stock valued at $6,780,000 after purchasing an additional 223,505 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Selecta Biosciences by 15.9% in the second quarter. Nuveen Asset Management LLC now owns 2,149,076 shares of the company’s stock valued at $8,983,000 after purchasing an additional 294,222 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in Selecta Biosciences by 34.6% in the second quarter. Alliancebernstein L.P. now owns 110,400 shares of the company’s stock valued at $461,000 after purchasing an additional 28,400 shares in the last quarter. Institutional investors and hedge funds own 70.05% of the company’s stock.

Selecta Biosciences stock remained flat at $$3.18 during mid-day trading on Thursday. 659,427 shares of the company’s stock were exchanged, compared to its average volume of 1,245,667. Selecta Biosciences has a 1 year low of $2.67 and a 1 year high of $5.70. The firm has a market cap of $370.94 million, a price-to-earnings ratio of -6.12 and a beta of 1.01. The firm has a fifty day moving average of $4.04.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.

Recommended Story: Asset Allocation

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.